about
Towards a rational design of solid drug nanoparticles with optimised pharmacological properties.Interactions between tenofovir and nevirapine in CD4+ T cells and monocyte-derived macrophages restrict their intracellular accumulation.Rilpivirine inhibits drug transporters ABCB1, SLC22A1, and SLC22A2 in vitroEfavirenz Is Predicted To Accumulate in Brain Tissue: an In Silico, In Vitro, and In Vivo Investigation.Misoprostol-induced fever and genetic polymorphisms in drug transporters SLCO1B1 and ABCC4 in women of Latin American and European ancestry.A multisystem investigation of raltegravir association with intestinal tissue: implications for pre-exposure prophylaxis and eradication.Antiretroviral solid drug nanoparticles with enhanced oral bioavailability: production, characterization, and in vitro-in vivo correlation.Development and validation of an LC-MS/MS assay for the quantification of efavirenz in different biological matrices.Prioritisation of potential anti-SARS-CoV-2 drug repurposing opportunities based on ability to achieve adequate target site concentrations derived from their established human pharmacokineticsDose prediction for repurposing nitazoxanide in SARS-CoV-2 treatment or chemoprophylaxis
P50
Q30372133-9FCB4A19-24A1-4D37-B27B-FCAA7213B0BAQ37232200-796A515C-6412-4A0B-BF89-1EDB7F88609CQ37263486-9355296A-C118-412B-8A97-1C8CC89B3186Q37538717-0F234BA1-87B6-4A53-AE5D-C4FAA9AF64CFQ38858861-4825337C-C349-4F43-9F6D-C6A91EF76798Q39273607-DDB4C9EC-9502-4A8B-822A-9398E4CF4C7EQ46448056-53EFBDD3-97DC-48FF-9FED-EBC00B5C8EAAQ47817799-9E1999A5-4204-485B-9C92-B445A85C29C6Q95601629-D82F8D55-9E73-4C18-A780-0C6CE375BD33Q95614621-286B0570-E9FC-4328-AD08-986D382AA48D
P50
description
researcher ORCID ID = 0000-0003-4596-2708
@en
wetenschapper
@nl
name
Paul Curley
@ast
Paul Curley
@en
Paul Curley
@es
Paul Curley
@nl
type
label
Paul Curley
@ast
Paul Curley
@en
Paul Curley
@es
Paul Curley
@nl
prefLabel
Paul Curley
@ast
Paul Curley
@en
Paul Curley
@es
Paul Curley
@nl
P106
P31
P496
0000-0003-4596-2708